Related Experiment Video

Updated: Aug 14, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Attenuation of experimental colonic injury by thiazolidinedione agents

K Takaki1, K Mitsuyama, O Tsuruta

  • 1Second Department of Medicine, Kurume University School of Medicine, Asahi-machi 67, Kurume 830-0011, Japan.

Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|December 6, 2005
PubMed
Abstract

Insights

Thiazolidinedione (TZD) agonists, pioglitazone and netoglitazone, effectively treated dextran sulfate sodium (DSS)-induced colitis in mice. These agents reduced inflammation by down-regulating key inflammatory signaling pathways.

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Immunology

Background:

  • Inflammatory bowel disease (IBD) poses a significant health challenge.
  • Peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists, like thiazolidinediones (TZDs), have shown anti-inflammatory properties.
  • Understanding the precise mechanisms of TZDs in intestinal inflammation is crucial for developing new therapies.

Purpose of the Study:

  • To investigate the therapeutic potential of pioglitazone and netoglitazone (TZD agonists) in a mouse model of dextran sulfate sodium (DSS)-induced colitis.
  • To elucidate the action mechanisms of these TZDs in mitigating intestinal inflammation.

Main Methods:

  • Colitis was induced in mice using 2.5% DSS for 7 days.
  • TZDs (pioglitazone, netoglitazone) were administered either prophylactically (2 days before DSS) or therapeutically (2 days after DSS induction).
  • Pro-inflammatory cytokine signaling, including interleukin-6 (IL-6) and phospho-signal transducer and activator of transcription-3 (p-STAT3), was assessed in vivo and in vitro.

Main Results:

  • Both pioglitazone and netoglitazone significantly attenuated DSS-induced colitis when administered prophylactically.
  • Pioglitazone also demonstrated therapeutic efficacy in treating established colitis.
  • Treatment with pioglitazone was associated with reduced colonic IL-6 and p-STAT3 levels.
  • In vitro studies confirmed that pioglitazone down-regulated IL-6 production in lamina propria mononuclear cells.

Conclusions:

  • Thiazolidinedione (TZD) agents, specifically pioglitazone and netoglitazone, show promise as novel therapeutic agents for intestinal inflammation, including inflammatory bowel disease.
  • The anti-inflammatory effects of TZDs are partly mediated by the down-regulation of pro-inflammatory cytokine signaling pathways.

More Related Videos

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)12:37

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)

Published on: September 11, 2012

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...